137 related articles for article (PubMed ID: 8546383)
1. Retroviral vectors for HIV immunotherapy.
Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
[No Abstract] [Full Text] [Related]
2. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
[TBL] [Abstract][Full Text] [Related]
4. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.
Buffa V; Negri DRM; Leone P; Bona R; Borghi M; Bacigalupo I; Carlei D; Sgadari C; Ensoli B; Cara A
J Gen Virol; 2006 Jun; 87(Pt 6):1625-1634. PubMed ID: 16690927
[TBL] [Abstract][Full Text] [Related]
5. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T-lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector-transduced autologous fibroblasts expressing HIV-1IIIB Env/Rev proteins.
Ziegner UH; Peters G; Jolly DJ; Mento SJ; Galpin J; Prussak CE; Barber JR; Hartnett DE; Bohart C; Klump W
AIDS; 1995 Jan; 9(1):43-50. PubMed ID: 7893440
[TBL] [Abstract][Full Text] [Related]
7. Induction of anti-HIV-1 immune responses by retroviral vectors.
Jolly DJ; Warner JF
Biotechnol Ther; 1991; 2(1-2):179-93. PubMed ID: 1845120
[TBL] [Abstract][Full Text] [Related]
8. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects.
Haubrich R; McCutchan JA; Holdredge R; Heiner L; Merritt J; Merchant B
Hum Gene Ther; 1995 Jul; 6(7):941-55. PubMed ID: 7578412
[No Abstract] [Full Text] [Related]
9. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies.
Krohn K; Stanescu I; Blazevic V; Vesikari T; Ranki A; Ustav M
Microbes Infect; 2005 Nov; 7(14):1405-13. PubMed ID: 16257560
[TBL] [Abstract][Full Text] [Related]
10. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.
MacGregor RR; Boyer JD; Ciccarelli RB; Ginsberg RS; Weiner DB
J Infect Dis; 2000 Jan; 181(1):406. PubMed ID: 10608800
[No Abstract] [Full Text] [Related]
11. Vaccine therapy using rgp 160 in early HIV infection.
Redfield R; Birx D; Ketter N; Polonis V; Johnson S; Davis C; Smith G; Oster C; Burke D
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1333. PubMed ID: 1361350
[No Abstract] [Full Text] [Related]
12. DNA inoculation induces cross clade anti-HIV-1 responses.
Wang B; Boyer J; Srikantan V; Ugen K; Agadjanian M; Merva M; Gilbert L; Dang K; McCallus D; Moelling K
Ann N Y Acad Sci; 1995 Nov; 772():186-97. PubMed ID: 8546392
[TBL] [Abstract][Full Text] [Related]
13. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
14. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
Xin KQ; Urabe M; Yang J; Nomiyama K; Mizukami H; Hamajima K; Nomiyama H; Saito T; Imai M; Monahan J; Okuda K; Ozawa K; Okuda K
Hum Gene Ther; 2001 Jun; 12(9):1047-61. PubMed ID: 11399227
[TBL] [Abstract][Full Text] [Related]
15. Vaccines based on Nef and on Nef/DeltaV2 Env.
Erfle V; Goebel FD; Guzman CA; Le Grand R
Microbes Infect; 2005 Nov; 7(14):1400-4. PubMed ID: 16243564
[TBL] [Abstract][Full Text] [Related]
16. Intracellular immunization or immunotherapy for HIV infection?
Featherstone C
Mol Med Today; 1996 Jul; 2(7):271. PubMed ID: 8796904
[No Abstract] [Full Text] [Related]
17. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells.
Warner JF; Anderson CG; Laube L; Jolly DJ; Townsend K; Chada S; St Louis D
AIDS Res Hum Retroviruses; 1991 Aug; 7(8):645-55. PubMed ID: 1931234
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
[No Abstract] [Full Text] [Related]
19. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
20. Retroviral-mediated expression of FIV envelope/Rev induces CD8+ CTL responses in mice.
von Schwedler U; Townsend K; Chada S; Jolly DJ; Elder J; Chang SM; Lee WT
Intervirology; 1997; 40(4):271-6. PubMed ID: 9612729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
